脓毒症初始管理中的低容量与高容量液体治疗:系统评价、Meta分析与试验序贯分析
该系统评价纳入9项2015年后发表的随机临床试验(n=637),比较成人脓毒症低容量与高容量静脉液体治疗,所有试验总体偏倚风险高。主要结局全因死亡率(RR 0.87;95%CI 0.69-1.10;I²=0%;TSA校正CI 0.34-2.22)和严重不良事件(RR 0.91;95%CI 0.78-1.05;I²=0%;TSA校正CI 0.68-1.21)均无统计学显著差异,无试验报告生活质量。次要和探索性结局未见差异,所有结局证据质量极低。结论认为支持成人脓毒症静脉液体容量决策的证据数量和质量均极低。
要点
- 成人脓毒症低容量 vs 高容量液体:全因死亡率 RR 0.87(95%CI 0.69-1.10;I²=0%;TSA校正CI 0.34-2.22),无统计学显著差异。
- 严重不良事件 RR 0.91(95%CI 0.78-1.05;I²=0%;TSA校正CI 0.68-1.21),低容量与高容量之间无统计学显著差异。
- 无试验报告生活质量结局,次要和探索性结局亦未见差异;所有结局证据质量极低。
- 纳入的9项试验(n=637)均为2015年后发表,总体偏倚风险高,TSA校正后置信区间宽。
适用人群与场景
- 成人脓毒症患者,纳入随机临床试验的静脉液体容量分离研究。
研究设计与关键结果
- 系统评价纳入9项随机临床试验,共637例成人脓毒症患者,所有试验2015年后发表,总体偏倚风险高。
- 主要结局全因死亡率:低容量 vs 高容量 RR 0.87(95%CI 0.69-1.10;I²=0%;TSA校正CI 0.34-2.22),无统计学显著差异。
- 主要结局严重不良事件:低容量 vs 高容量 RR 0.91(95%CI 0.78-1.05;I²=0%;TSA校正CI 0.68-1.21),无统计学显著差异。
- 无试验报告生活质量;次要和探索性结局未见差异;所有结局证据质量极低。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析及试验序贯分析(TSA),纳入9项随机临床试验。
- 证据质量:所有结局证据质量极低。
- 局限:纳入试验总体偏倚风险高;TSA校正后置信区间宽(死亡率0.34-2.22,严重不良事件0.68-1.21);无试验报告生活质量。
对床旁实践的改变
- 作者结论:支持成人脓毒症静脉液体治疗容量决策的证据数量和质量均极低,低容量与高容量策略在全因死亡率和严重不良事件上无统计学显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: IV fluids are recommended during the initial management of sepsis, but the quality of evidence is low, and clinical equipoise exists. We aimed to assess patient-important benefits and harms of lower vs higher fluid volumes in adult patients with sepsis.
METHODS: We conducted a systematic review with meta-analysis and trial sequential analysis (TSA) of randomized clinical trials of IV fluid volume separation in adult patients with sepsis. We adhered to our published protocol; the Cochrane handbook; the Preferred Reporting Items for Systematic Reviews and Meta-Analyses; and the Grading of Recommendations Assessment, Development and Evaluation statements. The primary outcomes were all-cause mortality, serious adverse events (SAEs), and quality of life.
RESULTS: We included nine trials (n = 637); all were published after 2015 and had an overall high risk of bias. We found no statistically significant difference between lower vs higher fluid volumes in all-cause mortality (relative risk [RR], 0.87; 95% CI, 0.69-1.10; I2 = 0%; TSA-adjusted CI, 0.34-2.22) or SAEs (RR, 0.91; 95% CI, 0.78-1.05; I2 = 0%; TSA-adjusted CI, 0.68-1.21). No trials reported on quality of life. We did not find differences in the secondary or exploratory outcomes. The quality of evidence was very low across all outcomes.
CONCLUSIONS: In this systematic review, we found very low quantity and quality of evidence supporting the decision on the volumes of IV fluid therapy in adults with sepsis.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03668236; URL: www.clinicaltrials.gov.
参考来源
- Meyhoff TS, Møller MH, Hjortrup PB, et al. Lower vs Higher Fluid Volumes During Initial Management of Sepsis: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. Chest. 2020. PMID: 31982391. doi:10.1016/j.chest.2019.11.050
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。